These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 35162988)
1. GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition. Hathaway-Schrader JD; Norton D; Hastings K; Doonan BP; Fritz ST; Bethard JR; Blum JS; Haque A Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162988 [TBL] [Abstract][Full Text] [Related]
2. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Goldstein OG; Hajiaghamohseni LM; Amria S; Sundaram K; Reddy SV; Haque A Cancer Immunol Immunother; 2008 Oct; 57(10):1461-70. PubMed ID: 18343923 [TBL] [Abstract][Full Text] [Related]
3. Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. Nguyen J; Bernert R; In K; Kang P; Sebastiao N; Hu C; Hastings KT Melanoma Res; 2016 Apr; 26(2):125-37. PubMed ID: 26930048 [TBL] [Abstract][Full Text] [Related]
4. GILT in Thymic Epithelial Cells Facilitates Central CD4 T Cell Tolerance to a Tissue-Restricted, Melanoma-Associated Self-Antigen. Rausch MP; Meador LR; Metzger TC; Li H; Qiu S; Anderson MS; Hastings KT J Immunol; 2020 Jun; 204(11):2877-2886. PubMed ID: 32269095 [TBL] [Abstract][Full Text] [Related]
5. High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma. Buetow KH; Meador LR; Menon H; Lu YK; Brill J; Cui H; Roe DJ; DiCaudo DJ; Hastings KT J Immunol; 2019 Nov; 203(10):2577-2587. PubMed ID: 31591149 [TBL] [Abstract][Full Text] [Related]
6. Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells. Hathaway-Schrader JD; Doonan BP; Hossain A; Radwan FFY; Zhang L; Haque A J Cell Biochem; 2018 Feb; 119(2):2212-2221. PubMed ID: 28857256 [TBL] [Abstract][Full Text] [Related]
7. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223 [TBL] [Abstract][Full Text] [Related]
8. Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma. Norton DL; Haque A J Oncol; 2009; 2009():142959. PubMed ID: 20016802 [TBL] [Abstract][Full Text] [Related]
9. Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent. O'Donnell PW; Haque A; Klemsz MJ; Kaplan MH; Blum JS J Immunol; 2004 Jul; 173(2):731-5. PubMed ID: 15240658 [TBL] [Abstract][Full Text] [Related]
11. Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. Haque MA; Li P; Jackson SK; Zarour HM; Hawes JW; Phan UT; Maric M; Cresswell P; Blum JS J Exp Med; 2002 May; 195(10):1267-77. PubMed ID: 12021307 [TBL] [Abstract][Full Text] [Related]
12. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854 [TBL] [Abstract][Full Text] [Related]
13. GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity. Phipps-Yonas H; Semik V; Hastings KT Eur J Immunol; 2013 Jan; 43(1):65-74. PubMed ID: 23012103 [TBL] [Abstract][Full Text] [Related]
14. Diverse cellular and organismal functions of the lysosomal thiol reductase GILT. Rausch MP; Hastings KT Mol Immunol; 2015 Dec; 68(2 Pt A):124-8. PubMed ID: 26116226 [TBL] [Abstract][Full Text] [Related]
15. GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1. Rausch MP; Hastings KT J Invest Dermatol; 2012 Jan; 132(1):154-62. PubMed ID: 21833020 [TBL] [Abstract][Full Text] [Related]
16. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941 [TBL] [Abstract][Full Text] [Related]
17. Exposure of the promonocytic cell line THP-1 to Escherichia coli induces IFN-gamma-inducible lysosomal thiol reductase expression by inflammatory cytokines. Lackman RL; Cresswell P J Immunol; 2006 Oct; 177(7):4833-40. PubMed ID: 16982925 [TBL] [Abstract][Full Text] [Related]
18. An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen. Rausch MP; Hastings KT PLoS One; 2015; 10(4):e0123332. PubMed ID: 25875653 [TBL] [Abstract][Full Text] [Related]
19. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590 [TBL] [Abstract][Full Text] [Related]
20. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. Slager EH; Borghi M; van der Minne CE; Aarnoudse CA; Havenga MJ; Schrier PI; Osanto S; Griffioen M J Immunol; 2003 Feb; 170(3):1490-7. PubMed ID: 12538712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]